Diabetes Care:降低BMI分界点对美国亚裔人群糖尿病筛选的影响

2015-09-09 潘宗海 译 医学论坛网

2015年8月31日《糖尿病护理》(Diabetes Care)杂志在线版发表了一项新的研究结果:根据2015年最新修订的美国糖尿病诊疗标准,降低BMI分界点,研究这一该表对美国亚裔人群糖尿病筛选的影响。        该研究通过在2011年-2012年的美国全国健康和营养调查中将体重指数(BMI)分界点降低到23kg/m2,筛选在这个值以下的亚裔

2015年8月31日《糖尿病护理》(Diabetes Care)杂志在线版发表了一项新的研究结果:根据2015年最新修订的美国糖尿病诊疗标准,降低BMI分界点,研究这一该表对美国亚裔人群糖尿病筛选的影响。
        
该研究通过在2011年-2012年的美国全国健康和营养调查中将体重指数(BMI)分界点降低到23kg/m2,筛选在这个值以下的亚裔人群的糖尿病和糖尿病前期的发病率。研究纳入标准为:45岁及以上的非西班牙籍的亚裔人群,有详实的BMI、糖化血红蛋白、空腹血糖数据,共招募341例受试者。
        
研究结果显示:在把BMI指数降低到23kg/m2后,糖尿病前期和糖尿病的筛查敏感性从50.2%上升至74.1%(P<0.0001),但特异性从62.9%降低至38.7%(P<0.0001).
        
结论:用更低的BMI指数来筛查特定人群的糖尿病和糖尿病前期这一做法会增加额外的健康护理费用,但是却能使相关人群在一级和二级预防上受益。
        
原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637151, encodeId=0312163e15146, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 25 21:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759583, encodeId=4f751e595831e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 18 05:52:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901310, encodeId=3963190131083, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jul 15 03:52:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584345, encodeId=240115843451e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Fri Sep 11 07:52:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637151, encodeId=0312163e15146, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 25 21:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759583, encodeId=4f751e595831e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 18 05:52:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901310, encodeId=3963190131083, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jul 15 03:52:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584345, encodeId=240115843451e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Fri Sep 11 07:52:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637151, encodeId=0312163e15146, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 25 21:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759583, encodeId=4f751e595831e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 18 05:52:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901310, encodeId=3963190131083, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jul 15 03:52:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584345, encodeId=240115843451e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Fri Sep 11 07:52:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637151, encodeId=0312163e15146, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 25 21:52:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759583, encodeId=4f751e595831e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 18 05:52:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901310, encodeId=3963190131083, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jul 15 03:52:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584345, encodeId=240115843451e, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Fri Sep 11 07:52:00 CST 2015, time=2015-09-11, status=1, ipAttribution=)]

相关资讯

Circulation:吸烟显著增加糖尿病患者的总死亡率及心血管事件发生率

背景:糖尿病患者抽烟较为普遍,量化抽烟与患者死亡率和发病率危险因素相关性,对糖尿病患者的管理非常重要。我们对相关的前瞻性队列研究进行系统性综述和meta分析,评估抽烟与糖尿病患者总死亡率与心血管疾病发病率之间的关系。方法和结果:我们搜索2015年5月之前MEDLINE和EMBASE数据库中的文献,应用随机效应模型得到多变量校正相对危险度。一共包括89个队列研究。与抽烟相关的患者总死亡率(48个研究

Nature:糖尿病药物吡格列酮或可用于治疗白血病

药物研发中总有各种千奇百怪的“意外”。如果不是弗莱明在培养基上多看了一眼,或许青霉素的发现还会推迟许多年。而这些美丽的“意外”往往会进一步推动人类的进步。最近,一个国际研究团队就发现以往用于治疗糖尿病的药物——吡格列酮或许能够帮助人类更好的对抗白血病。 慢性粒细胞白血病(CML)是一种罕见疾病,每年英国境内有600人被诊断患有这种疾病。尽管市面上有数种畅销疗法,但并不适用于所有患者。此外,

ESC 2015:年轻糖尿病女性心脏病的发病风险可高达6倍

年轻糖尿病女性心脏病的发病风险可高达6倍研究发现年轻糖尿病女性可有高达6倍的心脏病发病风险,研究共纳入了7000名45岁及以下的女性。研究还指出,论心脏病的发病风险,吸烟较老龄大一些。心血管疾病主要影响老年人群,但是近些年来,年轻人(不分性别)的发病率也越来越高。据WHO统计,心血管疾病所致的女性死亡占女性总死亡的52%,而且这个比例正不断加大。心脏病发作患者中1%为年轻女性。与无MI病史的女性相

FDA批准**全天候可携带连续血糖仪

 美国食品药品管理局已经批准首款连续血糖仪(CGM)系统,连续血糖仪系统能将监测数据直接发送至智能手机,而无需特殊独立的接受器。 FDA于今年8月25日批准的首款连续血糖仪(CGM)系统为Dexcom公司的G5移动血糖监测系统。该血糖监测系统不仅适用于成年人,对2岁的儿童同样适用。该技术利用无线蓝牙技术植入传感器,将实时监测的血糖数据发送到iOS系统手机的APP上,例如苹果手机

Nature:常用糖尿病药物的抗癌作用

一项发表在9月2日《自然》(Nature)杂志上的新研究表明,将一些常用糖尿病药物添加到标准治疗中或可帮助消灭某种白血病形式中的耐药癌细胞。研究人员发现同时接受格列酮(glitazone,一类2型糖尿病药物)及标准CML药物伊马替尼治疗(Imatinib)的慢性粒细胞白血病(CML)患者可以在长达近5年的时间内疾病不复发。伊马替尼的商品名为格列卫(Gleevec),在控制慢性粒细胞白血病中有着令人

CSE 2015:翁建平教授从糖尿病分型谈精准医学

中华医学会第十四次全国内分泌学学术会议于在2015年8月26日~29日在南京召开。会上,中山大学附属第三医院翁建平教授做了题为“从糖尿病分型谈精准医学”的学术报告。现将精彩内容整理如下,以飨读者:翁建平教授首先举了4个病例,虽然都是糖尿病,但每个病例各有特点,有的临床诊断为2型糖尿病,有的还不能明确地分型。这些病例在临床上经常见到,那么我们怎么对这些病例进行精准地鉴别诊断,怎么判断治疗效果,如何精